Cellectar Biosciences, Inc.
CLRBNASDAQHealthcare● Active
$2.51
$-0.08(-3.09%)
Market Cap$8012020
P/E Ratio—
52W High$14.1
52W Low$2.43
Cellectar Biosciences, Inc. (CLRB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLRB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$1.33
Est. -$1.89 · +29.4%
Revenue
—
Est. $0.01B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS🔥 6-Quarter EPS Beat Streak
CLRB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.06
Rev. $1.94B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.06
Rev. Est.$1.94B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.47 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$1.89 | -$1.33 | +29.4% | — | $0.01B | — |
| ▲ Q1 FY2026 | Mar 4, 2026 | -$1.19 | -$0.53 | +55.5% | — | $0.01B | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$1.91 | -$1.41 | +26.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$3.60 | -$3.39 | +5.8% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$5.11 | -$3.90 | +23.7% | — | — | — |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.38 | -$0.01 | +97.4% | — | — | — |
| ▼ Q4 FY2024 | Nov 18, 2024 | -$0.35 | -$16.52 | -4586.5% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.47
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$1.33
EPS Est.
-$1.89
EPS Surpr.
+29.4%
Revenue
—
Q1 FY2026
Mar 4, 2026Beat
EPS Actual
-$0.53
EPS Est.
-$1.19
EPS Surpr.
+55.5%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$1.41
EPS Est.
-$1.91
EPS Surpr.
+26.2%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$3.39
EPS Est.
-$3.60
EPS Surpr.
+5.8%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$3.90
EPS Est.
-$5.11
EPS Surpr.
+23.7%
Revenue
—
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.38
EPS Surpr.
+97.4%
Revenue
—
Q4 FY2024
Nov 18, 2024Miss
EPS Actual
-$16.52
EPS Est.
-$0.35
EPS Surpr.
-4586.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.79 | $-0.79 | $-0.79 | 1 |
| Q3 FY2027 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q2 FY2027 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q1 FY2027 | $-0.57 | $-0.57 | $-0.57 | 1 |
| Q4 FY2026 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Q3 FY2026 | $-0.43 | $-0.43 | $-0.43 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +29.4% | $2.94 | $3.20 | +8.84% |
| ▲ Q1 FY2026 | Mar 4, 2026 | +55.5% | $2.68 | $2.90 | +8.21% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +26.2% | $3.50 | $2.87 | -18.00% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +5.8% | $4.42 | $4.42 | +0.00% |
| ▲ Q2 FY2025 | May 13, 2025 | +23.7% | $7.92 | $7.20 | -9.09% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +97.4% | $9.50 | $8.99 | -5.37% |
| ▼ Q4 FY2024 | Nov 18, 2024 | -4586.5% | $55.80 | $53.10 | -4.84% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -217.4% | $55.80 | $60.60 | +8.60% |
Q2 FY2026+8.84%
Report Date
May 14, 2026
EPS Beat/Miss
+29.4%
Price Before
$2.94
Price After
$3.20
Q1 FY2026+8.21%
Report Date
Mar 4, 2026
EPS Beat/Miss
+55.5%
Price Before
$2.68
Price After
$2.90
Q4 FY2025-18.00%
Report Date
Nov 13, 2025
EPS Beat/Miss
+26.2%
Price Before
$3.50
Price After
$2.87
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
+5.8%
Price Before
$4.42
Price After
$4.42
Q2 FY2025-9.09%
Report Date
May 13, 2025
EPS Beat/Miss
+23.7%
Price Before
$7.92
Price After
$7.20
Q1 FY2025-5.37%
Report Date
Mar 13, 2025
EPS Beat/Miss
+97.4%
Price Before
$9.50
Price After
$8.99
Q4 FY2024-4.84%
Report Date
Nov 18, 2024
EPS Beat/Miss
-4586.5%
Price Before
$55.80
Price After
$53.10
Q3 FY2024+8.60%
Report Date
Aug 13, 2024
EPS Beat/Miss
-217.4%
Price Before
$55.80
Price After
$60.60
Avg Beat Reaction-2.57%
Avg Miss Reaction+1.88%
Beat Rate6 / 8 quarters
Largest Move-18.00% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLRB ends December
Cellectar Biosciences, Inc. (CLRB) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-1.33 — beating the analyst consensus of $-1.89 by +29.4%. CLRB has beaten EPS estimates for 6 consecutive quarters. The next CLRB earnings date is expected around September 1, 2026.
Each quarter, investors track CLRB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLRB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLRB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLRB earnings · 5 questionsCellectar Biosciences, Inc.'s next earnings report is expected around September 1, 2026. CLRB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLRB historically reports after market close (AMC).
CLRB earnings datewhen is CLRB earningsCLRB next earnings datewhen does CLRB report earningsCLRB earnings calendar
▸ Source: FMP · Cellectar Biosciences, Inc. SEC filings · US GAAP · Cellectar Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026